Octapharma is a company producing human proteins from human plasma and human cell lines. It develops and manufactures high-purity coagulation factor concentrates for patients with bleeding disorders; high-purity human immunoglobulin products for treating immune-mediated diseases and deficiencies and manufactures human plasma and protein products for treating critically ill or injured patients in intensive care and emergency settings. The company focuses on three therapeutic areas: haematology, immunotherapy, and critical care.